Minims Cyclopentolate Chlorhydrate Bausch + Lomb Ireland Limited (Cyclopentolate Hydrochloride)

Cyclopentolate Hydrochloride, the active ingredient in Minims Cyclopentolate Chlorhydrate, is an anticholinergic (muscarinic antagonist) presented as an ophthalmic solution for ocular use. It produces cycloplegia and mydriasis to facilitate detailed eye examinations and certain intra‑ocular procedures in adults and children.

GNH USA supplies Minims Cyclopentolate Chlorhydrate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance through reliable logistics and dedicated customer support. Our network ensures timely delivery to diverse markets.

Cyclopentolate Hydrochloride is used in ophthalmology to induce pharmacologic dilation and paralysis of the ciliary muscle.

Cycloplegic eye examination: provides cycloplegia for accurate refraction measurement. Retinal examination: creates mydriasis to allow thorough fundus evaluation. Anterior segment surgery: facilitates intra‑ocular procedures by maintaining pupil dilation. Uveitis assessment: temporarily immobilizes the iris to aid in inflammation evaluation. Pediatric eye assessment: enables reliable measurement of refractive error in children.

Cyclopentolate ophthalmic solution may cause ocular and systemic adverse reactions, ranging from mild to serious.

Common Side Effects: - Transient blurred vision - Photophobia (light sensitivity) - Mild ocular discomfort or stinging - Conjunctival redness - Increased tearing - Slight rise in intra‑ocular pressure - Mild headache - Nausea

Serious or Rare Side Effects: - Acute angle‑closure glaucoma - Severe allergic reaction such as anaphylaxis - Persistent mydriasis lasting >24 hours - Vision loss - Systemic anticholinergic toxicity (e.g., confusion, tachycardia, dry mouth) Patients should report any worsening symptoms promptly.

When using Cyclopentolate ophthalmic drops, several precautions should be observed to ensure safety and effectiveness.

- Assess angle status: avoid use in patients with narrow‑angle or uncontrolled glaucoma. - Check for hypersensitivity: discontinue if allergic signs such as rash or swelling appear. - Use caution in pediatric patients: higher systemic absorption may occur, requiring careful monitoring. - Avoid concurrent use with other mydriatic or cholinergic agents: may lead to excessive pupil dilation. - Pregnancy and lactation: safety category unknown; prescribe only when clearly indicated. - Store at room temperature: keep in original container, protect from light and moisture.

Cyclopentolate can interact with other medicines, altering its ocular effect or systemic profile.

Major Interactions (Avoid): - Other anticholinergic agents (e.g., atropine): additive mydriasis and cycloplegia. - Systemic cholinesterase inhibitors (e.g., physostigmine): antagonistic effect reducing drug action. - Topical beta‑blockers: may exacerbate intra‑ocular pressure changes.

Moderate Interactions (Monitor Closely): - Topical prostaglandin analogues: possible fluctuations in intra‑ocular pressure. - Systemic antihistamines or antidepressants with anticholinergic properties: increased systemic side effects. - Contact lens wear: may reduce drug absorption and efficacy.